Solventum Corporation $SOLV Holdings Boosted by General American Investors Co. Inc.

General American Investors Co. Inc. grew its holdings in Solventum Corporation (NYSE:SOLV – Free Report) by 6.4% in the first quarter, Holdings Channel.com reports. The firm owned 377,350 shares of the company’s stock after purchasing an additional 22,700 shares during the period. Solventum comprises approximately 1.6% of General American Investors Co. Inc.’s investment portfolio, making the stock its 19th largest position. General American Investors Co. Inc.’s holdings in Solventum were worth $24,641,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. United Services Automobile Association purchased a new position in Solventum during the 1st quarter valued at about $239,000. Woodline Partners LP boosted its holdings in Solventum by 40.7% during the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after acquiring an additional 3,377 shares during the period. Intech Investment Management LLC grew its position in shares of Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after purchasing an additional 10,425 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Solventum by 5.8% in the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock worth $19,546,000 after purchasing an additional 14,151 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Solventum during the 2nd quarter worth about $766,000.

Get Solventum alerts:

Solventum Price Performance

Shares of SOLV stock traded up $0.76 during mid-day trading on Friday, reaching $76.72. The company’s stock had a trading volume of 532,926 shares, compared to its average volume of 1,263,437. The firm’s 50-day moving average is $76.24 and its two-hundred day moving average is $74.32. The company has a market cap of $13.29 billion, a P/E ratio of 9.40, a PEG ratio of 1.18 and a beta of 0.66. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07.

Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business’s revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SOLV shares. UBS Group downgraded Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Thursday, May 14th. BMO Capital Markets began coverage on shares of Solventum in a research report on Wednesday. They set a “market perform” rating and a $81.00 target price on the stock. Piper Sandler reduced their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. KeyCorp raised their price target on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Stifel Nicolaus cut their price objective on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $83.50.

Check Out Our Latest Stock Analysis on SOLV

Solventum Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

See Also

• Five stocks we like better than Solventum
• 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
• Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
• Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
• This Dividend ETF Choice Could Shape Your Income Strategy Through 2026

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.